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Abstract 
Background/Aims: SOX9 is an important transcription factor required for development 
and has been implicated in several types of malignant tumor. Our recent study showed that 
SOX9 played an important role in multi-step carcinogenesis in cases of intraductal papillary 
mucinous tumor of the pancreas (IPMN-P). This study aimed to investigate the expression 
of SOX9 in cases of intraductal papillary mucinous tumor of the bile duct (IPMN-B).  
Material and Methods: SOX9 expression was immunohistochemically evaluated in the 
tumor and corresponding normal bile-duct epithelium of seven IPMN-B patients.  
Results: In all cases, SOX9 expression in the IPMN-B was low compared with the normal 
biliary epithelium. 
Conclusion: This study demonstrated that SOX9 expression may indicate a link between 
IPMN-B and IPMN-P. SOX9 may also have potential as a therapeutic target and/or 
prognostic marker in IPMN-B. 
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Introduction 
Some papillary bile duct tumors produce a large amount of mucin and cause several clinical 
symptoms including obstructive jaundice, abdominal pain, and fever. Mucin impedes the 
bile flow and causes biliary dilatation. Mucin-producing bile duct tumor is a rare disorder 
of the biliary tract, and several medical terms have been used to describe this tumor. Given 
its low incidence, the clinical features, diagnostic problems, and treatment strategies for this 
disorder are largely unclear [1-3]. “Intraductal papillary mucinous tumor of the bile duct” 
(IPMN-B) has been the most common term used to describe this condition in recent 
publications [4, 5]. IPMN-B is recognized as the counterpart of intraductal papillary 
mucinous tumor of the pancreas (IPMN-P) [6-8]. IPMN-B closely resembles IPMN-P in 
pathological characteristics and postoperative survival status [9, 10].  
Recent reports have implicated Sex-determining Region Y (SRY) box 9 (SOX9), 
an important transcription factor required for development, in several types of malignant 
tumor [11-13]. In addition, SOX9 is an essential regulator for biliary development [14]. Our 
recent study showed that SOX9 plays an important role in the multi-step carcinogenesis of 
IPMN-P [15]. Herein, we described the SOX9 expression in IPMN-B and reveal the role of 
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Materials and methods 
Patients 
From 1993 to 2011, seven patients with IPMN-B underwent surgery in our department. The 
profiles of our patients are summarized in Table 1. There were 4 females and 3 males, with 
a mean age of 68 years (range 61-76) at presentation. Five patients typically presented with 
recurrent cholangitis or jaundice while two patients were asymptomatic. A 
biliary-associated disease was found in three patients: hepatolithiasis in two and 
choledochoduodenal fistula in one. Major laboratory tests (total bilirubin, alkaline 
phosphatase, transaminases) were elevated in all five symptomatic patients but not in the 
two others. Serum carcinoembryonic antigen was within normal limits in all seven patients. 
Another tumor marker, CA19-9, was elevated in three patients. All laboratory tests, 
including tumor markers, were within normal limits in the two asymptomatic patients. 
Major diagnostic procedures including computed tomography (CT), ultrasonography (US), 
and endoscopic retrograde cholangiography (ERC) were performed in all seven patients. In 
all patients, ERC showed filling defects in the biliary tract the production of abundant 
mucin cause the orifice to be wide-open. ERC showed generalized dilatation of the intra- 
and extra-hepatic bile ducts in three patients, left hepatic duct and extra-hepatic bile ducts 
in two patients, right hepatic duct and extra-hepatic bile ducts in one patient, and segmental 
dilatation of the left hepatic ducts in one patient. Intraductal masses were revealed on 
enhanced CT in all patients. All patients underwent curative hepatectomy. Histological 
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grade findings showed four invasive carcinomas, one noninvasive carcinoma, and two 
adenomas. Two patients died of recurrence. Two patients died of other disease. The other 
three patients are alive and disease-free. 
Immunohistochemical analysis 
All the surgical specimens were fixed in 10% formalin. The specimens were then sectioned, 
and serial sections were carefully cut from paraffin blocks and stained with hematoxylin 
and eosin. Immunohistochemical examinations were performed as follows. Sections were 
deparaffinized by ethanol concentrations and washed in phosphate-buffered saline (PBS). 
Then, the sections were treated with hot water at 95°C for antigen retrieval (Target 
Retrieval Solutions pH 9.0 (Dako, Japan)) for 20 minutes. After washing, the samples were 
treated with 0.03% hydrogen peroxide in methyl alcohol. Thereafter, they were treated with 
0.25% casein in PBS, containing stabilizing protein and 0.015 mol/L sodium azide (Protein 
Block, Serum-Free, Dako, Japan) at room temperature for 20 min and covered with a 
mouse monoclonal antibody to SOX9 (Abcam Discover More, Tokyo, Japan) at a dilution 
of 1:500 in PBS at room temperature for 30 minutes. After being rinsed with PBS, the 
sections were treated with a rabbit polyclonal antibody against mouse IgG, IgA, and IgM at 
room temperature for 30 minutes and washed with PBS. The peroxidase/antiperoxidase 
complex was allowed to react with the rabbit antibody, and the sections were stained with 3, 
3-diaminobenzidinetetrahydrochloride (DAB) containing 0.03% hydrogen peroxide 
(Envison kit / HRP (DAB), Dako, Japan). The sections were counterstained with Mayer’s 
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hematoxylin.  
Expression of SOX9 was evaluated by the percentage of positive cells of each 
tumor specimen and that of the corresponding normal epithelium of the bile ducts. The 
percentages were analyzed by counting 200 cells at ×200 magnification in four random 
views. 
Statistical analysis 
Continuous data are expressed as the median (range). Categorical data and continuous data 
were compared using the Mann Whitney-U test. We assigned statistical significance at < 
0.05. The calculations were performed with the help of Excel statistics version 2009 (Social 












T. Kuroki et al. 
Results 
SOX9 positivity was detected in nuclei and was observed throughout the normal biliary 
epithelium. The results of the immunohistochemical analyses of SOX9 expression are 
presented in Table 2. Almost all normal biliary duct epithelial cells were SOX9 positive 
(Fig. 1). The SOX9-positive rate ranged from 75% to 83% in normal biliary epithelia. In 
comparison, all cases showed low SOX9 expression in IPMN-B (Fig. 2). The range of the 
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Discussion 
The expression of SOX9 was decreased in IPMN-B compared with the corresponding 
normal bile ducts in this immunohistochemical study. Our recent study demonstrated that 
the expression of SOX9 in pancreatic cancer was extremely low, and that in IPMN-P, SOX9 
expression progressively and gradually decreased according to IPMN-P progression, 
including adenoma, noninvasive carcinoma, and invasive carcinoma [15]. Recent studies 
have revealed that the IPMN-B is a counterpart of IPMN-P in terms of its histopathological 
features, production of a large amount of mucin, and clinical findings [4-10]. IPMN-B 
comprises a histological spectrum that ranges from benign to malignant: adenoma, 
noninvasive, and invasive carcinoma [16, 17]. Interestingly, the SOX9 expression in the 
two cases of adenoma of IPMN-B was higher than that in the more malignant cases of 
carcinoma of IPMN-B in the present study. The down-regulation of SOX9 expression is an 
early event in the stepwise carcinogenesis of IPMN-B. This same phenomenon was found 
in the stepwise carcinogenesis of IPMN-P [15]. 
 SOX9 was originally known as a key regulator of development processes, 
including chondrogenesis, neurogenesis, and male sex determination [18, 19]. Subsequently, 
SOX9 was shown to be a multifaceted transcription factor indispensable for the 
development of several organs, including the intestines, the pancreas, and the biliary tract 
[20]. Recent studies have shown the important role of SOX9 in carcinogenesis for several 
organs [21-]. Sun et al. [21] reported that upregulation of SOX9 is related to gastric cancer 
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development. Lu et al. [22] reported that SOX9 overexpression in colorectal cancer as an 
indicator of an unfavorable outcome. On the other hand, SOX9 expression in melanoma is 
downregulated; SOX9 overexpression in melanoma cell lines inhibited tumorigenicity in a 
human ex vivo model of melanoma [23]. In biliary tract cancers, a recent study 
demonstrated that lack of nuclear SOX9 expression was associated with a higher tumor 
stage [24]. Moreover, SOX9 is strongly expressed both in intrahepatic bile ducts and 
gallbladder epithelium [24]. The present study showed that SOX9-positive cells were 
expressed in almost all normal bile duct cells. It is clearly neither an oncogenic gene or 
anti-oncogenic gene but rather one that plays different roles in different cancers. 
Interestingly, Passeron et al. [23] reported that treatment of melanoma cell lines with 
prostaglandin D2 increased SOX9 expression and restored sensitivity to retinoic acid. 
These findings suggested that SOX9 has a potential to inhibit the growth of IPMN-B at an 
early, low-malignancy stage.  
 In summary, our results of SOX9 expression may indicate a link between 
IPMN-B and IPMN-P and confirm the recently proposed notion that these two 
mucin-producing cancers are counterparts. SOX9 may also have potential as a therapeutic 
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FIGURE LEGENDS 
Fig. 1 SOX9 expression and immunohistochemical stain of biliary epithelium. Almost all 
normal biliary duct epithelial cells were SOX9 positive. 
 






Table 1   Clinicopathologic findings of seven patients with IPMN-B 
 
No. Age Sex Location  Operation     Histological Grade  Outcome 
1 72 M Left hepatic duct Left trisectionectomy   Invasive carcinoma   25 months 
      Caudate lobectomy        Death of  
      Resection of the extrahepatic bile duct     other disease 
2 62 F Left hepatic duct Left hemihepatectomy   Noninvasive carcinoma 97 months 
      Caudate lobectomy        Death of  
                recurrence 
3 70 M Hilar duct  Right hemihepatectomy   Invasive carcinoma  25 months 
      Caudate lobectomy        Death of 
      Resection of the extrahepatic bile duct     recurrence 
4 62 F Common bile duct Anterior segmentectomy   Invasive carcinoma  79 months 
      Resection of the extrahepatic bile duct     Death of 
                Other disease 
5 61 F Left hepatic duct Left hemihepatectomy   Adenoma   142 months 
                Alive and  
                disease-free 
6 76 F Left hepatic duct Left hemihepatectomy   Adenoma   27 months 
      Caudate lobectomy        Alive and 
                disease-free 
7 76 M Right hepatic duct Extended right hemihepatectomy  Invasive carcinoma  50 months 
      Caudate lobectomy        Alive and 
      Resection of the extrahepatic bile duct     disease-free 
 
Table 2   SOX9 expression in seven patients with IPMN-B 
 
No.   SOX9 positive rate 
 Normal epithelial cells    tumor cells 
1  75%    31% 
2  77%    22% 
3  79%    19% 
4  77%    33% 
5  76%    36% 
6  83%    45% 
7  77%     7% 
 
